Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib + Ipilimumab in Advanced Melanoma
NCT04996823Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2021
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib, ipilimumab in melanoma, sponsored by Moffitt Cancer Center. Started Aug 2021; status: active, not recruiting.
02
Drugs
axitinibipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04996823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996823.